Quotient Clinical, a business unit of Quotient Bioresearch ("Quotient"), today announced the completion of a major expansion of its clinical facilities in Nottingham, UK. Bed capacity has been increased by 50 per cent and a dedicated sample processing laboratory for human ADME studies has been incorporated. The new facilities have been inspected and approved for use by the UK regulatory authority, the Medicines and Healthcare products Regulatory Agency (MHRA), and have been awarded Supplementary Accreditation.    

The expansion is a direct response to increasing customer adoption of Quotient's Synthesis-to-Clinic™ platform, in particular in support of human ADME studies, and reinforces Quotient's position as a leading provider of 14C-enabled drug development services including Phase 0 microdose, ivMicrotracerTM, and human metabolism studies.

Synthesis-to-Clinic integrates each component required to undertake a 14C-enabled clinical study into a single supply chain, spanning 14C API radiosynthesis through to the clinical study report.  The ability to seamlessly deliver such a program under a single contract, with a single project manager and continuity of scientific input throughout, delivers significant benefits to the drug development project team.

Mark Egerton, MD Quotient Clinical, commented:  "In parallel with the recent expansion of our Pharmaceutical Sciences laboratory and GMP drug product manufacturing facility, the completion of this clinical expansion is another milestone in the development of our business. It underlines the strength of our Synthesis-to-Clinic platform and the benefits it brings to our global client base. Our expanded facilities will assist the continued development of our services, supporting our customers in taking new and innovative approaches in early drug development."